Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 14/20 | 0.67 |
| ▸ | KDR | P35968 | 8/20 | 0.62 |
| ▸ | CDK4 | P11802 | 3/20 | 0.60 |
| ▸ | CCND1 | P24385 | 3/20 | 0.60 |
| ▸ | CCND3 | P30281 | 3/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 4/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3917597 | 1.00 | CHEK1 (0.67) | CHEK1KDRCDK4CCND1CCND3 | |
| SCHEMBL5508124 | 0.86 | CHEK1 (0.61) | CHEK1KDRCDK4CCND1CCND3 | |
| SCHEMBL5508123 | 0.86 | CHEK1 (0.61) | CHEK1KDRCDK4CCND1CCND3 | |
| SCHEMBL5511824 | 0.82 | CHEK1 (0.78) | CHEK1KDRCDK4CCND1CCND3 | |
| SCHEMBL17982219 | 0.82 | CHEK1 (0.57) | CHEK1KDRCDK4CCND1CCND3 | |
| SCHEMBL5511827 | 0.82 | CHEK1 (0.78) | CHEK1KDRCDK4CCND1CCND3 | |
| SCHEMBL17982218 | 0.82 | CHEK1 (0.57) | CHEK1KDRCDK4CCND1CCND3 | |
| SCHEMBL11924700 | 0.81 | CHEK1 (0.56) | CHEK1KDRCDK4CCND1CCND3 | |
| SCHEMBL2458766 | 0.80 | CHEK1 (0.67) | CHEK1KDRCDK4CCND1CCND3 | |
| SCHEMBL2458765 | 0.80 | CHEK1 (0.67) | CHEK1KDRCDK4CCND1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732938-B1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-05-06 | — | — | EP | disclosed |
| US-7491710-B2 | Organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2009-02-17 | — | — | US | disclosed |
| CN-1894264-A | Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2007-01-10 | — | — | CN | disclosed |
| EP-1732938-A1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005058923-A1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2005-06-30 | — | — | WO | disclosed |
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | PPIP5K2, INPPL1, IP6K3 | CHEK1 43/4885KDR 2842/4885CDK4 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.